MIIST305: A first-in-class immunomodulatory therapeutic


Relief from gut injury caused by cancer therapies

MIIST305 is designed to reduce toxicity to the GI tract from cancer treatments, allowing patients to safely tolerate higher treatment doses needed to aggressively treat their cancer. In animal models, MIIST305 reduces chemical or radiation-induced mortality by reducing the activation of innate inflammatory pathways, restoring GI mucosal defenses, and preventing mucosal barrier breakdown that leads to bacterial translocation and possibly sepsis.

Deriving from our Multivalent Innate Immune Signaling Target (MIIST) platform, MIIST305 has been shown to promote healing and reduce inflammation at the damaged tissue surface. In addition, this restoration of a healthy gut environment has been shown to promote normal commensal flora and prevent overgrowth of pathogenic bacteria. Expansion indications include graft-versus-host disease, and GI damage caused by acute radiation syndrome.

How MIIST305 targets immunomodulatory signaling

The cells lining the intestine are coated with a thick, natural glycopolymer layer called the glycocalyx. Radiation and chemotherapy damage the glycocalyx, reducing protective function and initiating an innate immune system response. The resulting local inflammation initiates circulating cytokines and chemokines that trigger systemic inflammation. MIIST305 acts at the mucosal surface to reduce activation of TLR’s and immune signaling, repairing and resetting the fundamental mucosal role as a protective barrier against infection and further damage.